Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial ratios display a consistent improvement in the company's leverage and coverage metrics over the five-year period from 2020 through 2024. Analysis reveals a positive trend toward lower reliance on debt and stronger ability to cover interest and fixed charges.
- Debt to Equity Ratios
- Both the standard debt to equity ratio and the one including operating lease liabilities demonstrate a steady decline, falling from 0.57 to 0.30 and from 0.61 to 0.32 respectively. This indicates a gradual reduction in debt relative to shareholders’ equity, reflecting a strengthening equity base or a reduction in borrowed capital.
- Debt to Capital Ratios
- Debt to capital ratios, with and without operating lease liabilities, show a downward trajectory, decreasing from 0.36 to 0.23 and 0.38 to 0.24 correspondingly. The trend signals a decreasing proportion of debt in the company’s overall capital structure, enhancing financial stability.
- Debt to Assets Ratios
- The company’s debt relative to total assets also reduces across the period, moving from 0.26 to 0.17 and from 0.27 to 0.19 when leases are included. This reduction suggests the company is less leveraged in terms of asset base financing, which can be indicative of lower financial risk.
- Financial Leverage
- The financial leverage ratio declines consistently from 2.21 to 1.71. This downtrend implies a decrease in total asset financing by debt, enhancing the equity portion and potentially increasing solvency.
- Interest Coverage Ratio
- The interest coverage ratio initially increases sharply from 10.1 in 2020 to 16.41 in 2021, slightly decreases but remains strong at 15.89 in 2022, then dips to 11.46 in 2023 before improving again to 13.55 in 2024. Despite some fluctuations, the overall ratio stays at comfortable levels above 10, indicating solid capacity to meet interest obligations from operational earnings.
- Fixed Charge Coverage Ratio
- The fixed charge coverage ratio follows a pattern similar to the interest coverage ratio, rising from 6.68 in 2020 to over 10 in 2021 and 2022, then declining to 7.71 in 2023 and modestly recovering to 8.58 in 2024. This pattern suggests relatively stable, though somewhat variable, ability to cover fixed financial charges, with improved coverage compared to the start of the period.
Overall, the trends point toward strengthening financial health characterized by declining leverage and consistently adequate coverage of interest and fixed charges. This progression may imply prudent debt management and growing earnings power in relation to financial obligations.
Debt Ratios
Coverage Ratios
Debt to Equity
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Total Abbott shareholders’ investment | ||||||
Solvency Ratio | ||||||
Debt to equity1 | ||||||
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Debt to Equity, Sector | ||||||
Health Care Equipment & Services | ||||||
Debt to Equity, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals several key trends over the five-year period ending in 2024. The company has consistently reduced its total debt, decreasing from 18,747 million US dollars in 2020 to 14,125 million US dollars in 2024. This downward trajectory signals a strategic focus on deleveraging and improving financial stability.
Correspondingly, shareholders' investment increased steadily, rising from 32,784 million US dollars in 2020 to 47,664 million US dollars in 2024. This increase likely reflects retained earnings accumulation, equity issuance, or other forms of capital enhancement, contributing to a stronger equity base.
The ratio of debt to equity has shown a consistent decline, dropping from 0.57 in 2020 to 0.30 in 2024. This declining ratio corroborates the simultaneous decrease in debt and the increase in shareholders’ equity, indicating improved capital structure and lower financial leverage over time. The trend suggests an enhanced capacity to absorb financial shocks and potentially better creditworthiness.
- Total Debt
- Demonstrates a clear downward trend, indicating active debt reduction from 18,747 million to 14,125 million over five years.
- Shareholders' Investment
- Shows continuous growth, rising from 32,784 million to 47,664 million, representing stronger equity financing and retained value.
- Debt to Equity Ratio
- Declined steadily from 0.57 to 0.30, reflecting decreasing reliance on debt and improving balance sheet strength.
In summary, the data indicates a deliberate financial strategy to reduce liabilities while enhancing equity, resulting in a healthier, less risky financial posture. This trend may appeal to investors and creditors focusing on stability and sustainable growth.
Debt to Equity (including Operating Lease Liability)
Abbott Laboratories, debt to equity (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Operating lease liability, current (included in Other accrued liabilities) | ||||||
Operating lease liability, non-current | ||||||
Total debt (including operating lease liability) | ||||||
Total Abbott shareholders’ investment | ||||||
Solvency Ratio | ||||||
Debt to equity (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Debt to Equity (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | ||||||
Debt to Equity (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
- Total Debt (Including Operating Lease Liability)
- The total debt of the entity has demonstrated a consistent downward trend over the five-year period. Beginning at 19,890 million US dollars at the end of 2020, it steadily decreased each year, reaching 15,275 million US dollars by the end of 2024. This reflects an overall reduction in debt of approximately 23.2%, indicating a strategic move towards deleveraging and potentially strengthening the organization's financial stability.
- Total Shareholders’ Investment
- Shareholders' investment shows a continuous upward trajectory from 32,784 million US dollars at the end of 2020 to 47,664 million US dollars by the end of 2024. The increase appears steady and significant, especially notable between 2023 and 2024 with a considerable jump of over 9,000 million US dollars. This growth suggests enhanced equity value, possibly due to retained earnings, capital injections, or stock issuance, indicating strengthened net assets and increased shareholder value.
- Debt to Equity Ratio (Including Operating Lease Liability)
- The debt to equity ratio has steadily decreased from 0.61 in 2020 to 0.32 in 2024. This decline reflects an improvement in the company's capital structure, signifying a reduced reliance on debt financing relative to shareholders' equity. A lower ratio typically suggests lower financial risk, enhancing creditworthiness and potentially lowering the cost of capital.
- Summary
- Over the analyzed period, the company exhibits a clear trend of reducing leverage while simultaneously increasing shareholder investment. The decreasing total debt coupled with an expanding equity base leads to a significant decline in the debt to equity ratio. These changes suggest a strategic focus on strengthening the balance sheet by lowering financial risk and increasing net worth, which could improve long-term financial flexibility and stability.
Debt to Capital
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Total Abbott shareholders’ investment | ||||||
Total capital | ||||||
Solvency Ratio | ||||||
Debt to capital1 | ||||||
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Debt to Capital, Sector | ||||||
Health Care Equipment & Services | ||||||
Debt to Capital, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The financial data indicates a consistent downward trend in the total debt levels over the analyzed period. Starting at 18,747 million US dollars at the end of 2020, total debt decreased steadily each year, reaching 14,125 million by the end of 2024. This represents a considerable reduction in debt obligations over the five-year span.
Total capital exhibited a relatively stable trend from 2020 through 2023, fluctuating slightly around the 51,000 to 53,800 million US dollars range. However, there is a notable increase in total capital in 2024, with the figure rising to 61,789 million, indicating an expansion in the company's capital base in the most recent year.
The debt to capital ratio shows a clear and continuous decline throughout the period. Beginning at 0.36 in 2020, the ratio decreased each year, ending at 0.23 in 2024. This suggests an improving capital structure, with the company relying less on debt relative to its total capital over time. The combination of decreasing total debt and increasing total capital, especially in the final year, underscores a strengthening financial position and potentially greater financial stability and flexibility.
- Total Debt
- Decreased from 18,747 million US dollars in 2020 to 14,125 million in 2024, indicating successful debt reduction strategies.
- Total Capital
- Remained stable around mid-50,000 million from 2020 to 2023, followed by a marked increase to 61,789 million in 2024.
- Debt to Capital Ratio
- Declined consistently from 0.36 in 2020 to 0.23 in 2024, reflecting reduced leverage and improved capital structure.
Debt to Capital (including Operating Lease Liability)
Abbott Laboratories, debt to capital (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Operating lease liability, current (included in Other accrued liabilities) | ||||||
Operating lease liability, non-current | ||||||
Total debt (including operating lease liability) | ||||||
Total Abbott shareholders’ investment | ||||||
Total capital (including operating lease liability) | ||||||
Solvency Ratio | ||||||
Debt to capital (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Debt to Capital (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | ||||||
Debt to Capital (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data over the five-year period reveals several notable trends in the company's capital structure and debt management.
- Total Debt (Including Operating Lease Liability)
- The total debt has shown a consistent decline from 19,890 million US dollars in 2020 to 15,275 million US dollars in 2024. This represents a reduction of approximately 23.2% over the five years, indicating a strategic effort to reduce leverage and improve financial stability.
- Total Capital (Including Operating Lease Liability)
- Total capital remained relatively stable between 2020 and 2023, fluctuating slightly from 52,674 million US dollars to 54,476 million US dollars. However, in 2024, there was a significant increase to 62,939 million US dollars, marking a rise of about 15.5% compared to the previous year. This increase suggests either new equity issuance, retained earnings growth, or a combination thereof, contributing to a stronger capital base.
- Debt to Capital Ratio (Including Operating Lease Liability)
- The debt to capital ratio has steadily decreased from 0.38 in 2020 to 0.24 in 2024. This declining ratio signifies a lower proportion of debt financing relative to total capital over time. The trend reflects enhanced financial robustness with reduced reliance on debt, improving the company's risk profile and potentially lowering financing costs.
Overall, the data illustrates a deliberate shift toward deleveraging and strengthening the capital structure. By lowering total debt and increasing total capital, the company has improved its financial leverage position, which can enhance its creditworthiness and provide a more solid foundation for future growth initiatives.
Debt to Assets
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets1 | ||||||
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Debt to Assets, Sector | ||||||
Health Care Equipment & Services | ||||||
Debt to Assets, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data indicates several notable trends regarding the company's capital structure and asset base over the five-year period ending December 31, 2024.
- Total Debt
- Total debt has demonstrated a consistent downward trend from US$18,747 million in 2020 to US$14,125 million in 2024. This represents an overall reduction of approximately 24.6% over the period, indicating a deliberate strategy to reduce leverage or improve debt management.
- Total Assets
- Total assets exhibited moderate fluctuations, initially increasing slightly from US$72,548 million in 2020 to a peak of US$75,196 million in 2021. Subsequently, assets declined gradually to US$73,214 million by the end of 2023 before rising significantly to US$81,414 million in 2024. This increase in the final year suggests renewed asset growth or investment activity.
- Debt to Assets Ratio
- The ratio of total debt to total assets decreased steadily from 0.26 in 2020 to 0.17 in 2024. This decline reflects improved financial leverage, indicating that the company relied less on debt relative to its asset base over time. The reduction aligns with the observed decrease in total debt and the eventual growth in total assets.
Overall, the data suggests a strengthening balance sheet with reduced financial risk due to lower debt levels and an expanding asset base, particularly notable in the most recent year. The company appears to prioritize deleveraging while supporting asset growth, resulting in enhanced capitalization and potentially greater financial flexibility.
Debt to Assets (including Operating Lease Liability)
Abbott Laboratories, debt to assets (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt | ||||||
Long-term debt, excluding current portion | ||||||
Total debt | ||||||
Operating lease liability, current (included in Other accrued liabilities) | ||||||
Operating lease liability, non-current | ||||||
Total debt (including operating lease liability) | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Debt to Assets (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | ||||||
Debt to Assets (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several key trends regarding the company's debt and asset management over the five-year period.
- Total debt (including operating lease liability)
- The total debt shows a consistent downward trend from 19,890 million US dollars in 2020 to 15,275 million US dollars in 2024. This indicates a clear reduction in leverage or borrowing over the years, with a total decrease of approximately 23.2% across the period.
- Total assets
- Total assets initially increased slightly from 72,548 million US dollars in 2020 to 75,196 million US dollars in 2021. However, there was a mild decline in the following years, reaching 73,214 million US dollars in 2023. In 2024, a notable increase occurred, raising total assets to 81,414 million US dollars. Overall, total assets experienced moderate growth, especially in the latest year after a period of relative stability.
- Debt to assets ratio (including operating lease liability)
- The debt to assets ratio steadily declined from 0.27 in 2020 to 0.19 in 2024. This decrease aligns with the observed reduction in total debt and indicates an improvement in the company’s capital structure, reflecting a lower proportion of debt financing relative to total assets over time.
In summary, the company has been reducing its debt levels consistently while maintaining a stable and growing asset base. The decreasing debt to assets ratio suggests enhanced financial stability and potentially lower financial risk. The significant growth in assets in the final year of the analysis may indicate new investments, acquisitions, or asset revaluations contributing to an improved balance sheet strength.
Financial Leverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Total assets | ||||||
Total Abbott shareholders’ investment | ||||||
Solvency Ratio | ||||||
Financial leverage1 | ||||||
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Financial Leverage, Sector | ||||||
Health Care Equipment & Services | ||||||
Financial Leverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data over the five-year period reveals several important trends related to the company's asset base, shareholder equity, and financial leverage.
- Total assets
- The total assets exhibit moderate fluctuation from 2020 to 2023, decreasing slightly from US$72,548 million in 2020 to US$73,214 million in 2023, with a minor dip in 2022. However, in 2024, there is a noticeable increase to US$81,414 million, representing significant asset growth compared to previous years.
- Total Abbott shareholders’ investment
- The shareholders' investment shows a steady upward trend throughout the period. Starting at US$32,784 million in 2020, it increases consistently each year, reaching US$47,664 million by 2024. This indicates an improvement in equity financing or retained earnings, enhancing the company’s net worth.
- Financial leverage
- The financial leverage ratio steadily declines from 2.21 in 2020 to 1.71 in 2024. This reduction suggests a decrease in reliance on debt relative to equity. A lower leverage ratio generally reflects a more conservative capital structure and potentially reduced financial risk.
Overall, the data indicates that while total assets were relatively stable in the earlier years, asset growth accelerates notably in the latest year. Concurrently, shareholders' equity consistently increases, improving the company's financial stability. The ongoing decrease in financial leverage further reinforces a trend towards a stronger equity base and lower dependency on external financing.
Interest Coverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | ||||||
Less: Net earnings from discontinued operations, net of taxes | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Solvency Ratio | ||||||
Interest coverage1 | ||||||
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Interest Coverage, Sector | ||||||
Health Care Equipment & Services | ||||||
Interest Coverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
- Earnings Before Interest and Tax (EBIT)
- The EBIT showed a significant increase from 2020 to 2021, rising from 5,514 million US dollars to 8,744 million US dollars. In 2022, EBIT remained relatively stable at 8,864 million US dollars, indicating a peak performance period. However, in 2023, there was a notable decline to 7,301 million US dollars, followed by a slight recovery to 7,572 million US dollars in 2024. Overall, the EBIT demonstrates an initial strong growth trajectory, followed by a decline and partial recovery in latest periods.
- Interest Expense
- The interest expense remained relatively stable over the analyzed periods, fluctuating slightly around mid-500 million US dollars. It started at 546 million in 2020, decreased marginally to 533 million in 2021, then increased to 558 million in 2022 and peaked at 637 million in 2023 before falling back to 559 million in 2024. This pattern suggests moderate variability in interest costs without pronounced upward or downward trends.
- Interest Coverage Ratio
- The interest coverage ratio, reflecting the company's ability to meet its interest obligations from EBIT, showed a strong position throughout the periods. It rose significantly from 10.1 in 2020 to 16.41 in 2021, indicating enhanced coverage and reduced risk. The ratio slightly decreased to 15.89 in 2022 but remained high. In 2023, the coverage ratio dropped more noticeably to 11.46, reflecting the decrease in EBIT alongside an increase in interest expense. In 2024, the ratio rebounded to 13.55, indicating a partial improvement in the company’s capacity to cover interest obligations. Overall, the interest coverage remained well above acceptable thresholds, despite some volatility related to EBIT fluctuations.
Fixed Charge Coverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings | ||||||
Less: Net earnings from discontinued operations, net of taxes | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Add: Operating lease cost | ||||||
Earnings before fixed charges and tax | ||||||
Interest expense | ||||||
Operating lease cost | ||||||
Fixed charges | ||||||
Solvency Ratio | ||||||
Fixed charge coverage1 | ||||||
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Fixed Charge Coverage, Sector | ||||||
Health Care Equipment & Services | ||||||
Fixed Charge Coverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
- Earnings before fixed charges and tax
- The earnings before fixed charges and tax showed a significant increase from 5,843 million USD in 2020 to a peak of 9,219 million USD in 2022. However, the figure declined in 2023 to 7,657 million USD, before slightly recovering to 7,938 million USD in 2024. This pattern indicates strong growth initially, followed by some volatility and a moderate rebound.
- Fixed charges
- Fixed charges increased steadily over the five-year period with a rise from 875 million USD in 2020 to 993 million USD in 2023, before decreasing to 925 million USD in 2024. This suggests a general upward trend in fixed financial obligations, with a slight reduction in the most recent year.
- Fixed charge coverage
- The fixed charge coverage ratio experienced a marked improvement from 6.68 in 2020 to a peak of 10.21 in 2021, maintaining a similar level at 10.1 in 2022. Subsequently, it declined to 7.71 in 2023 but showed improvement again to 8.58 in 2024. This trend reflects the fluctuations in the company's ability to cover fixed charges, correlating with the changes in earnings and fixed charges.